Vascepa's future could hinge on next week's panel
Amarin’s Vascepa is widely expected to receive approval in a huge new patient population. So why has the company not been bought?
First blood: Rubius approaches its big test
The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…
Iterum’s antibiotic is far from a Sure thing
Iterum should soon find out if it has an approvable asset in the antibiotic sulopenem, but even if the group succeeds it still has a hard road ahead.
Triple meeting – clinical data, and competition, loom for Mirati
Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
Genfit’s liver disease Hail Mary approaches
Genfit's quiet delay means it will be five years since a Nash failure before investors find out whether pressing on into phase III was worth it.
Wave takes a different tack from Sarepta in Duchenne
Wave will soon report key early-stage data with its exon-skipping DMD candidate suvodirsen but, unlike Sarepta, the group is starting its confirmatory trial before…
A ternary outcome for Tocagen
Tocagen’s Toca-5 trial has survived two interim reviews, and faces final readout by the end of this year.
Reata gets another shot in Friedreich’s ataxia
Reata Pharmaceuticals will soon find out if its decision to persevere with omaveloxolone despite an earlier failure has paid off.
Medicines Company goes on the hunt for heartening Orion data
The Medicines Company needs to show decent efficacy and pristine safety with its long-lasting PCSK9 inclisiran to stand a chance of disrupting the market.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.